SPRO
Spero Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.21
−0.82%Year over year
Reported trailing growth
- Revenue
- -7.0%
- EBITDA
- +113.7%
- EBIT
- +110.5%
- EPS
- +114.1%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +7.1%
- EBITDA
- -43.0%
- EBIT
- +100.0%
- Net income
- -38.7%
- EPS
- -40.9%
- Free cash flow
- +46.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026